You searched for: blood brain barrier (Engelska - Maltesiska)

blood-brain barrier
barriera ematoenċefalika

passage of the blood brain barrier is low.
passaġġ tal-barriera ta’ bejn id-demm u l-moħħ huwa baxx.

dopamine does not cross the blood-brain barrier.
dopamine ma jaqsamx il-barriera ta’ bejn id-demm u l-moħħ.

clinically important disruptions of the blood-brain barrier
tfixkil klinikament importanti tal-barriera tad-demm tal-moħħ

penetration of ceftazidime into the intact blood-brain barrier is poor.
il-penetrazzjoni ta' ceftazidime fil-barriera intatta bejn id-demm u l-moħħ hija dgħajfa.

prilocaine crosses the blood-brain barrier and also crosses the placenta.
prilocaine jaqsam il-barriera tad-demm-moħħ u jaqsam ukoll il-plaċenta.

caution should be exercised in children with compromised blood brain barrier eg.
għandha tintuża l-kawtela fi tfal b'barriera bejn id-demm u l-moħħ kompromessa eż.

asparaginase does not seem to penetrate the blood-brain barrier in measurable amounts.
ma jidhirx li asparaginase jista’ jippenetra l-barriera tad-demm-moħħ f’ammonti li jistgħu jitkejlu.

the blood brain barrier integrity is important for minimizing naloxegol uptake into the cns.
l-integrità tal-barriera ta’ bejn id-demm u l- moħħ hija importanti biex jitnaqqas it-teħid ta’ naloxegol fis-cns.

lidocaine can cross the blood brain barrier and the placenta and is distributed in breast milk.
lidocaine jista’ jaqsam il-barriera tad-demm-moħħ u l-plaċenta u jiġi distribwit fil-ħalib tas-sider.

dexmedetomidine is also rapidly distributed in the body and penetrates the blood-brain barrier readily.
dexmedetomidine jinfirex ukoll malajr mal-ġisem u jgħaddi faċilment mid-demm għal ġol-moħħ.

studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier.
studji fuq il- firien b' montelukast radjutikkettat jindikaw distribuzzjoni minima tul il- barriera bejn id- demm u l- moħħ.

hydrochlorothiazide crosses the placental but not the blood-brain barrier, and is excreted in breast milk.
hydrochlorothiazide jgħaddi mill-plaċenta iżda mhux mill-barriera bejn il-moħħ u d-demm, u jitneħħa fil-ħalib tas-sider.

these studies in rats with radiolabeled roflumilast also indicate low penetration across the blood-brain barrier.
dawn l-istudji li saru fuq il-firien b’roflumilast radjutikkettat ukoll jindikaw penetrazzjoni baxxa minn naħa għall-oħra tal-barriera demm-moħħ.

fampridine is a lipid-soluble medicinal product which readily crosses the blood-brain barrier.
fampridine hu prodott mediċinali li jinħall fil-lipidi u li jgħaddi mingħajr tfixkil mid-demm għall- moħħ.

the major circulating metabolite is the 10-n-glucuronide, which does not pass the blood brain barrier.
il-prodott metaboliku li l-aktar jiċċirkola huwa 10-n- glukoronide, li ma jaqsamx il-barriera bejn id-demm u l-moħħ.

in preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys.
fi studji ta' qabel l-użu kliniku, instab li pregabalin jaqsam il-barriera ta' bejn id-demm u l-moħħ fil- ġrieden, firien u xadini.

pet studies in humans and preclinical data suggest that tmz crosses the blood-brain barrier rapidly and is present in the csf.
studji pet fil-bniedem u dejta ta’ qabel l-użu kliniku jindikaw li tmz jaqsam malajr mill-barriera ta’ bejn id-demm u l-moħħ u jinstab fis-csf.

in ms, lesions are believed to occur when activated t-lymphocytes cross the blood-brain barrier (bbb).
f’ms, huwa maħsub li l-leżjonijiet jseħħu meta l-limfoċiti-t attivati jaqsmu l-barriera ta’ bejn id-demm u l-moħħ (bbb).

care should be exercised in patients with severe cardiac disease and in patients with injuries of the blood brain barrier and severe cerebral disease.
wieħed għandu joqgħod attent f’ kaz li l- pazjenti jkollhom mard serju tal- qalb u f’ pazjenti li għandhom feriti fil- membrana tad- demm tal- moħħ u mard serju ċelebrali.